The European Commission conducted a surprise inspection at Edwards Lifesciences Corp's (NYSE: EW) facility within a European Union member state due to suspicions of potential market power abuse, possibly infringing upon the EU's antitrust regulations.
Pliant Therapeutics Inc (NASDAQ: PLRX) announced data from the INTEGRIS-PSC Phase 2a trial of bexotegrast in patients with primary sclerosing cholangitis (PSC) and suspected
Inozyme Pharma Inc (NASDAQ: INZY) announced interim safety, pharmacokinetic (PK), pharmacodynamic (PD), and exploratory efficacy data from its ongoing Phase 1/2 trials of INZ-701 in adults with
Ionis Pharmaceuticals Inc (NASDAQ: IONS) released topline results for the Phase 3 Balance study of olezarsen in people with familial chylomicronemia syndrome (FCS), a hereditary disease that prevents the body from breaking down fats.
Candel Therapeutics Inc (NASDAQ: CADL) announced updated activity data from its ongoing, open-label, phase 2 trial of CAN-2409 plus valacyclovir in combination with continued immune checkpoint inhibitor (ICI) treatment in patients with non-resectable, stage III/IV non-small cell l
Omega Therapeutics Inc (NASDAQ: OMGA) announced preliminary data from the initial two dose level cohorts (n=8) from Part 1 of its Phase 1/2 MYCHELANGELO I study of OTX-2002 in hepatocellular carcinoma and other solid tumors associated
European countries are actively negotiating a fresh COVID-19 vaccine procurement agreement with Moderna Inc (NASDAQ: MRNA) as concerns mount within EU health authorities regarding a surge in coronavirus infections.
Despite significant initiatives by generic drug companies to broaden access to vital medicines, many vulnerable patients remain underserved, according to findings from a new study from the Access to Medicine Foundation.
Immunovant Inc (NASDAQ: IMVT), a unit of Roivant Sciences Ltd (NASDAQ: ROIV), announced that subcutaneously administered doses of IMVT-1402 produced dose-dependent reductions in Immunoglobulin G (IgG) in